Navigation

CROHN´S/IBS/STOMACH RELATED ISSUES

â€¹Return to Previous Page

Cannabidiol in inflammatory bowel diseases: a brief overview (PubMed)

Cannabis finds its way into treatment of Crohn’s disease (PubMed)

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis (PubMed)

The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis (PubMed)

Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice(PubMed)

Cannabinoids and the gut: New developments and emerging concepts (PubMed)

Endocannabinoids and the gastrointestinal tract (PubMed)

Cannabinoids and gastrointestinal motility: Animal and human studies (PubMed)

Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis(O’Shaughnessy’s)

Cannabidiol in inflammatory bowel diseases: A brief overview (PubMed)

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)

Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)

Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation (PubMed)

Therapeutic potential of cannabinoid-based drugs (PubMed)

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology) (PubMed)

Cannabinoids and the gut: New developments and emerging concepts (PubMed)

Endocannabinoids and the gastrointestinal tract (PubMed)

Cannabinoids and gastrointestinal motility: Animal and human studies (PubMed)

Mobile version: Enabled

Back to top